Medical technology company RaySearch Laboratories AB (publ) (STO:RAY-B) announced on Wednesday that it has secured orders for its RayStation treatment planning system from Institut de Cancérologie de Lorraine, Centre Jean Perrin, and Centre Hospitalier Universitaire de Limoges, under the Unicancer 2019 Framework agreement.
The orders, valued at EUR3.2m excluding service contracts, were placed in summer 2024, with one third recognized in Q2 and two thirds in Q3.
Unicancer, a French hospital network specializing in oncology, comprises 18 comprehensive cancer centres and two affiliated centres. 14 Unicancer centres and two public hospitals have adopted RayStation through the 2019/PPE019 Framework agreements.
RayStation and RayCare have now been selected in the 2023 Unicancer Framework agreement, effective August 2024. Unicancer treats over 600,000 patients annually and manages 787 ongoing clinical trials.
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Shenzhen Chipscreen Biosciences' IND application for CS231295 tablets accepted in China
Sanofi and Orano partner to advance radioligand therapies
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
RaySearch secures RayStation orders from French cancer centers under Unicancer agreement
Merck's CAPVAXIVE shows promising immune responses in adults at risk of pneumococcal disease
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient